American Association for Cancer Research

SHERPA: Unknown

People

  1. Kris
    Kris
  2. Miller
    Miller
  3. Riely
    Riely
  4. Ladanyi
    Ladanyi
  5. Pao
    Pao
  6. Sirotnak
    Sirotnak
  7. Krug
    Krug
  8. Arcila
    Arcila
  9. Azzoli
    Azzoli
  10. Tyson
    Tyson

Groups

  1. Department of Medicine (39)
  2. Solid Tumor Oncology Division (39)
  3. Thoracic Oncology (37)
  4. GSK Faculty (16)
  5. Department of Pathology and Laboratory Medicine (14)
  6. Human Oncology and Pathogenesis Program (14)
  7. Tow Center for Developmental Oncology (TCDO) (14)
  8. Radiology, Department of (9)
  9. Nursing (8)
  10. Body Imaging Service (6)
Search Within
  1. "Vincent Miller"
Formats
  1. Journal Article (35)
  2. Meeting Abstract (8)
Groups
  1. Department of Medicine (39)
  2. Solid Tumor Oncology Division (39)
  3. Thoracic Oncology (37)
  4. GSK Faculty (16)
  5. Department of Pathology and Laboratory Medicine (14)
  6. Human Oncology and Pathogenesis Program (14)

More Groups

People
  1. Vincent Miller (43)
  2. Mark Kris (32)
  3. Gregory Riely (16)
  4. Marc Ladanyi (14)
  5. William Pao (13)
  6. Francis Sirotnak (12)

More People

Years
  1. 2013 (1)
  2. 2012 (2)
  3. 2011 (7)
  4. 2010 (2)
  5. 2009 (1)
  6. 2008 (2)

More Years

Publications
  1. Clinical Cancer Research (39)
  2. Cancer Research (4)

Results (43)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Journal Article

    Yu, H. A.; Arcila, M. E.; Rekhtman, N.; Sima, C. S.; Zakowski, M. F.; Pao, W.; Kris, M. G.; Miller, V. A.; Ladanyi, M.; Riely, G. J.
    Clinical Cancer Research (2013)

    Fulltext@MSK | Save
  • RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer
    Meeting Abstract

    Ohashi, K.; Chmielecki, J.; Lin, Y. L.; Pan, H. L.; Vnencak-Jones, C.; Arcila, M.; Wang, L.; Fernandez, L.; Keisuke, A.; Shien, K.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • EGFR exon 19 insertions: A new family of sensitizing EGFR mutations in lung adenocarcinoma
    Journal Article

    He, M.; Capelletti, M.; Nafa, K.; Yun, C. H.; Arcila, M. E.; Miller, V. A.; Ginsberg, M. S.; Zhao, B.; Kris, M. G.; Eck, M. J.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Journal Article

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Sima, C. S.; Kass, S. L.; Riely, G. J.; Pao, W.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design
    Journal Article

    Chaft, J. E.; Oxnard, G. R.; Sima, C. S.; Kris, M. G.; Miller, V. A.; Riely, G. J.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosinekinase inhibitors in lung cancer
    Journal Article

    Oxnard, G. R.; Arcila, M. E.; Chmielecki, J.; Ladanyi, M.; Miller, V. A.; Pao, W.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
    Journal Article

    Rizvi, N. A.; Rusch, V.; Pao, W.; Chaft, J. E.; Ladanyi, M.; Miller, V. A.; Krug, L. M.; Azzoli, C. G.; Bains, M.; Downey, R.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation
    Journal Article

    Oxnard, G. R.; Arcila, M. E.; Sima, C. S.; Riely, G. J.; Chmielecki, J.; Kris, M. G.; Pao, W.; Ladanyi, M.; Miller, V. A.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib
    Journal Article

    Janjigian, Y. Y.; Azzoli, C. G.; Krug, L. M.; Pereira, L. K.; Rizvi, N. A.; Pietanza, M. C.; Kris, M. G.; Ginsberg, M. S.; Pao, W.; Miller, V. A.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay
    Journal Article

    Arcila, M. E.; Oxnard, G. R.; Nafa, K.; Riely, G. J.; Solomon, S. B.; Zakowski, M. F.; Kris, M. G.; Pao, W.; Miller, V. A.; Ladanyi, M.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: